Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction - 09/08/11
Résumé |
Background |
In patients with cardiogenic shock (CS) complicating an acute myocardial infarction, a strategy of early revascularization (ERV) versus initial medical stabilization (IMS) improves survival. Intra-aortic balloon counterpulsation (IABC) provides hemodynamic support and facilitates coronary angiography and revascularization in CS patients.
Methods and Results |
We evaluated 499 patients with record of systemic hypoperfusion status as an early response to IABC from the SHOCK trial (n = 185) and registry (n = 314) to determine the association between rapid complete reversal of systemic hypoperfusion (CRH) after 30 minutes of IABC and in-hospital, 30-day and 1-year mortality. Rapid complete reversal of systemic hypoperfusion was highly associated with lower in-hospital mortality (29% versus 65%, P < .001) in all patients. In the SHOCK trial, among patients assigned to ERV versus IMS, 30-day mortality was 26% versus 29%, respectively, with CRH and 61% versus 81%, respectively, without CRH after commencing IABC. The corresponding 1-year mortality rates were 35% versus 52% for ERV and 69% versus 87% for IMS (interaction P ≥ .25 at both time points). After adjusting for important correlates of outcome (left ventricular ejection fraction, age, and randomization to ERV), a significant association remained between CRH and registry and trial in-hospital mortality (odds ratio 0.23, 95% CI 0.14-0.39, P < .001) and trial 1-year mortality (odds ratio .28, 95% CI 0.12-0.67, P < .001).
Conclusions |
In CS patients, CRH after commencing IABC was independently associated with improved in-hospital, 30-day and 1-year survival regardless of early revascularization. In CS patients, CRH with IABC is an important early prognostic feature.
Le texte complet de cet article est disponible en PDF.Plan
| Presented in part at the 76th Annual Scientific Sessions of the American Heart Association, Orlando, Florida, November 2003. |
|
| The SHOCK trial and registry and creation of the manuscript were supported by grants from the NHLBI (RO1-HL 50020 and HL 49970, 1994 to 1999, Bethesda, Maryland). |
Vol 162 - N° 2
P. 268-275 - août 2011 Retour au numéro
Article précédent
- Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy
- Sabe De, Allen G. Borowski, Heng Wang, Leah Nye, Baozhong Xin, James D. Thomas, W. H. Wilson Tang
- A multicenter comparison of established and emerging cardiac biomarkers for the diagnostic evaluation of chest pain in the emergency department
- Anju Bhardwaj, Quynh A. Truong, W. Frank Peacock, Kiang-Teck J. Yeo, Alan Storrow, Stephen Thomas, Kevin M. Curtis, Robert S. Foote, Hong K. Lee, Karen F. Miller, James L. Januzzi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?